Quality control in molecular genetic testing

[1]  R. Desnick,et al.  Quality assurance in molecular genetic testing laboratories. , 1999, JAMA.

[2]  M. Losekoot,et al.  A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease , 1999, European Journal of Human Genetics.

[3]  M. Hayden,et al.  Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence‐specific internal DNA standard , 1999, Clinical genetics.

[4]  E. Prence,et al.  A practical guide for the validation of genetic tests. , 1999, Genetic testing.

[5]  E. Dequeker,et al.  Evaluation of CFTR gene mutation testing methods in 136 diagnostic laboratories: report of a large European external quality assessment , 1998, European Journal of Human Genetics.

[6]  M. Reid,et al.  Medical Genetic Services in 31 Countries1: An Overview , 1997, European journal of human genetics : EJHG.

[7]  E. Dequeker,et al.  Genetic testing and quality control in diagnostic laboratories , 2000, Nature Genetics.

[8]  D. Barton,et al.  Retaining the Confidence of the Public in Molecular Genetic Testing – Quality Assurance , 2001, Public Health Genomics.

[9]  H. Zoghbi,et al.  Fourteen and counting: unraveling trinucleotide repeat diseases. , 2000, Human molecular genetics.

[10]  N. Holtzman,et al.  The new genetics: Genetic testing and public policy , 1998, BMJ.

[11]  X. Estivill,et al.  Recommendations for quality improvement in genetic testing for cystic fibrosis European Concerted Action on Cystic Fibrosis , 2000, European Journal of Human Genetics.

[12]  D. Barton,et al.  A comparison of methods for gene dosage analysis in HMSN type 1 , 2001, Journal of medical genetics.

[13]  W. Grody,et al.  Diversity of cystic fibrosis mutation-screening practices. , 1998, American journal of human genetics.

[14]  D. Ledbetter,et al.  Validation studies of SNRPN methylation as a diagnostic test for Prader-Willi syndrome. , 1996, American journal of medical genetics.

[15]  K. Klinger,et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.

[16]  M. Schwartz.  Genetic testing and the clinical laboratory improvement amendments of 1988: present and future. , 1999, Clinical chemistry.

[17]  R. Hegele,et al.  Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis , 1999, Nature Genetics.